Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 17 | 2024 | 867 | 4.400 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 674 | 2.970 |
Why?
|
| Percutaneous Coronary Intervention | 8 | 2024 | 168 | 2.420 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 860 | 2.280 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 252 | 2.060 |
Why?
|
| Pharmacovigilance | 3 | 2024 | 13 | 2.030 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 249 | 1.790 |
Why?
|
| Atrial Fibrillation | 12 | 2024 | 798 | 1.730 |
Why?
|
| Heart Arrest | 4 | 2023 | 159 | 1.710 |
Why?
|
| Stroke | 12 | 2024 | 1138 | 1.640 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2024 | 98 | 1.530 |
Why?
|
| Cardiovascular Diseases | 10 | 2024 | 821 | 1.480 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 1.460 |
Why?
|
| Catheter Ablation | 4 | 2024 | 140 | 1.360 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 120 | 1.340 |
Why?
|
| Humans | 85 | 2025 | 59512 | 1.310 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 172 | 1.260 |
Why?
|
| Treatment Outcome | 22 | 2025 | 5180 | 1.170 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2023 | 213 | 1.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2024 | 51 | 1.140 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 569 | 1.130 |
Why?
|
| Hospitalization | 19 | 2025 | 1287 | 1.080 |
Why?
|
| Cardiovascular Agents | 3 | 2023 | 101 | 1.010 |
Why?
|
| Hospital Mortality | 14 | 2025 | 846 | 0.980 |
Why?
|
| Heart Transplantation | 3 | 2024 | 159 | 0.950 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.910 |
Why?
|
| Bayes Theorem | 1 | 2024 | 105 | 0.910 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 95 | 0.890 |
Why?
|
| Myocardial Revascularization | 1 | 2024 | 71 | 0.880 |
Why?
|
| United States | 24 | 2025 | 7530 | 0.870 |
Why?
|
| Health Care Costs | 2 | 2022 | 204 | 0.860 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2023 | 14 | 0.860 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 274 | 0.850 |
Why?
|
| Risk Factors | 18 | 2024 | 5014 | 0.840 |
Why?
|
| Neoplasms | 9 | 2025 | 1250 | 0.830 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 17 | 0.830 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 258 | 0.830 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2023 | 45 | 0.830 |
Why?
|
| Recovery of Function | 1 | 2024 | 261 | 0.820 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 52 | 0.810 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 54 | 0.810 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 88 | 0.800 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 85 | 0.790 |
Why?
|
| Thrombectomy | 1 | 2024 | 206 | 0.790 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 155 | 0.790 |
Why?
|
| Mortality, Premature | 1 | 2021 | 6 | 0.780 |
Why?
|
| Inpatients | 9 | 2024 | 296 | 0.770 |
Why?
|
| Heart-Assist Devices | 5 | 2025 | 126 | 0.770 |
Why?
|
| Stroke Volume | 5 | 2024 | 321 | 0.760 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2025 | 115 | 0.760 |
Why?
|
| Hyperkalemia | 1 | 2021 | 23 | 0.750 |
Why?
|
| Medicare | 2 | 2023 | 600 | 0.740 |
Why?
|
| Hypotension | 1 | 2021 | 47 | 0.730 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 156 | 0.720 |
Why?
|
| Length of Stay | 9 | 2025 | 768 | 0.710 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 118 | 0.710 |
Why?
|
| Aged | 22 | 2025 | 13358 | 0.700 |
Why?
|
| Cardiovascular System | 1 | 2020 | 41 | 0.690 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2024 | 670 | 0.680 |
Why?
|
| Kidney Diseases | 1 | 2021 | 159 | 0.670 |
Why?
|
| Male | 26 | 2025 | 27582 | 0.670 |
Why?
|
| Female | 29 | 2025 | 30914 | 0.660 |
Why?
|
| Retrospective Studies | 16 | 2025 | 6013 | 0.640 |
Why?
|
| Dementia | 1 | 2022 | 247 | 0.630 |
Why?
|
| Adult | 25 | 2025 | 15776 | 0.630 |
Why?
|
| Secondary Prevention | 1 | 2019 | 154 | 0.630 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 750 | 0.580 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2024 | 77 | 0.580 |
Why?
|
| Young Adult | 10 | 2025 | 4326 | 0.560 |
Why?
|
| Atrial Appendage | 3 | 2022 | 28 | 0.560 |
Why?
|
| Cardiotoxicity | 4 | 2025 | 16 | 0.540 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2024 | 155 | 0.530 |
Why?
|
| Brain Ischemia | 1 | 2019 | 402 | 0.500 |
Why?
|
| Middle Aged | 17 | 2025 | 16278 | 0.460 |
Why?
|
| Databases, Factual | 4 | 2024 | 841 | 0.450 |
Why?
|
| Adolescent | 9 | 2025 | 5922 | 0.440 |
Why?
|
| Time Factors | 5 | 2024 | 3583 | 0.430 |
Why?
|
| Pandemics | 5 | 2023 | 610 | 0.400 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.400 |
Why?
|
| Myocarditis | 3 | 2024 | 61 | 0.400 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 13 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 75 | 0.390 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 90 | 0.370 |
Why?
|
| Hospitals | 6 | 2024 | 376 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 192 | 0.370 |
Why?
|
| Valsartan | 2 | 2021 | 11 | 0.370 |
Why?
|
| Aminobutyrates | 2 | 2021 | 10 | 0.370 |
Why?
|
| Tetrazoles | 2 | 2021 | 20 | 0.370 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 29 | 0.370 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 269 | 0.370 |
Why?
|
| Drug Combinations | 2 | 2021 | 137 | 0.360 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 63 | 0.350 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 5100 | 0.350 |
Why?
|
| Aortic Valve | 4 | 2024 | 170 | 0.340 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 131 | 0.330 |
Why?
|
| Atherosclerosis | 2 | 2021 | 147 | 0.320 |
Why?
|
| Ritonavir | 3 | 2023 | 14 | 0.320 |
Why?
|
| Hypertension | 2 | 2024 | 600 | 0.310 |
Why?
|
| Hemorrhage | 3 | 2024 | 268 | 0.290 |
Why?
|
| Shock, Cardiogenic | 2 | 2025 | 85 | 0.270 |
Why?
|
| Obesity | 2 | 2024 | 1186 | 0.260 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 60 | 0.260 |
Why?
|
| Anticoagulants | 4 | 2022 | 485 | 0.260 |
Why?
|
| Child | 3 | 2024 | 4313 | 0.250 |
Why?
|
| Mitral Valve | 2 | 2023 | 104 | 0.250 |
Why?
|
| Femoral Artery | 2 | 2023 | 93 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 211 | 0.250 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 263 | 0.240 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 537 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 17 | 0.240 |
Why?
|
| Canagliflozin | 1 | 2024 | 5 | 0.230 |
Why?
|
| Glucosides | 1 | 2024 | 13 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 34 | 0.230 |
Why?
|
| Perioperative Care | 1 | 2025 | 78 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 77 | 0.220 |
Why?
|
| Furosemide | 1 | 2023 | 17 | 0.220 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 48 | 0.220 |
Why?
|
| Ibuprofen | 1 | 2023 | 18 | 0.220 |
Why?
|
| Indomethacin | 1 | 2023 | 20 | 0.220 |
Why?
|
| Propensity Score | 1 | 2024 | 133 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2023 | 24 | 0.220 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 58 | 0.220 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 100 | 0.220 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 172 | 0.210 |
Why?
|
| Rural Population | 2 | 2022 | 191 | 0.210 |
Why?
|
| Prealbumin | 1 | 2023 | 20 | 0.210 |
Why?
|
| Catheterization, Peripheral | 1 | 2023 | 45 | 0.210 |
Why?
|
| Popliteal Artery | 1 | 2023 | 25 | 0.210 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 13 | 0.210 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 13 | 0.210 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 41 | 0.210 |
Why?
|
| Disability Evaluation | 1 | 2024 | 216 | 0.210 |
Why?
|
| Vascular Patency | 1 | 2023 | 132 | 0.210 |
Why?
|
| Paclitaxel | 1 | 2023 | 90 | 0.200 |
Why?
|
| Climate Change | 1 | 2022 | 16 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 151 | 0.200 |
Why?
|
| Reoperation | 1 | 2023 | 255 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2025 | 233 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1306 | 0.200 |
Why?
|
| Overweight | 1 | 2024 | 249 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2023 | 196 | 0.190 |
Why?
|
| Infant, Premature | 1 | 2023 | 174 | 0.190 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 31 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 109 | 0.190 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 144 | 0.190 |
Why?
|
| Algorithms | 2 | 2024 | 992 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 442 | 0.190 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2022 | 354 | 0.190 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2021 | 33 | 0.190 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 142 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 39 | 0.190 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 11 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 212 | 0.190 |
Why?
|
| Giant Cells | 1 | 2021 | 17 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2022 | 205 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 171 | 0.180 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 62 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 142 | 0.180 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Anemia | 1 | 2021 | 117 | 0.170 |
Why?
|
| Cardiology | 1 | 2022 | 164 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 66 | 0.170 |
Why?
|
| Cardiac Catheterization | 4 | 2022 | 246 | 0.170 |
Why?
|
| Asthma | 1 | 2023 | 419 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2023 | 421 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 421 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 160 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 645 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 567 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1136 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1124 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1118 | 0.120 |
Why?
|
| Comorbidity | 3 | 2023 | 1090 | 0.120 |
Why?
|
| Mortality | 2 | 2025 | 161 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2012 | 247 | 0.100 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 51 | 0.100 |
Why?
|
| Warfarin | 2 | 2022 | 109 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 46 | 0.090 |
Why?
|
| Coronary Angiography | 2 | 2023 | 172 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2443 | 0.070 |
Why?
|
| Pregnancy | 2 | 2024 | 2355 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2475 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 22 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 55 | 0.060 |
Why?
|
| Peripartum Period | 1 | 2024 | 31 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 85 | 0.060 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.060 |
Why?
|
| Spasm | 1 | 2023 | 9 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 11 | 0.050 |
Why?
|
| Diuretics | 1 | 2023 | 58 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 31 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 102 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 188 | 0.050 |
Why?
|
| Radial Artery | 1 | 2023 | 43 | 0.050 |
Why?
|
| Hematoma | 1 | 2023 | 74 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 93 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 13 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 109 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 123 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 113 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2022 | 71 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 48 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2024 | 521 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2022 | 56 | 0.050 |
Why?
|
| New Mexico | 1 | 2021 | 8 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 14 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 42 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 301 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 54 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2022 | 98 | 0.050 |
Why?
|
| Endocardium | 1 | 2021 | 12 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 164 | 0.050 |
Why?
|
| Troponin I | 1 | 2021 | 32 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 962 | 0.050 |
Why?
|
| California | 1 | 2021 | 161 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 52 | 0.050 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 254 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 314 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 261 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 165 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1286 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 308 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 553 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 393 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 459 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 375 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 185 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 303 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 923 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 276 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 425 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 524 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 889 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 541 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 1915 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1836 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1198 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1104 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3102 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2012 | 102 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 34 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 178 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1056 | 0.020 |
Why?
|